Bruker Takes Majority Stake in MIMETAS to Boost Human Physiology Drug Discovery
Event summary
- Bruker Corporation acquired a majority stake in MIMETAS, a developer of organ-on-a-chip platforms and human tissue models for drug discovery.
- The investment expands Bruker’s post-genomic solutions into Microphysiological Systems (MPS) and New Approach Methodologies (NAMs).
- MIMETAS’ OrganoPlate® platform combines microfluidic tissue cultures with standard microtiter-plate formats, supporting higher-throughput research workflows.
- Bruker plans to integrate MIMETAS’ capabilities with its technologies in proteomics, metabolomics, NMR, preclinical imaging, and spatial biology.
The big picture
Bruker’s investment in MIMETAS aligns with the broader industry trend toward human-relevant tissue models for drug discovery. This strategic move positions Bruker to capitalize on the growing demand for advanced, scalable organ-on-a-chip platforms that improve clinical translation and reduce reliance on animal testing.
What we're watching
- Integration Challenges
- How Bruker will merge MIMETAS’ organ-on-a-chip platforms with its existing molecular and cellular characterization technologies.
- Market Adoption
- The pace at which humanized Microphysiological Systems (MPS) will be adopted in drug discovery and preclinical testing.
- Regulatory Shifts
- Whether the transition away from animal testing will accelerate, driven by advancements in New Approach Methodologies (NAMs).
Related topics